

# Supplemental Figures

Erkizan et al. Cell Cycle





Ewing Sarcoma Antagonist Peptide (ESAP) number




Ewing Sarcoma Antagonist Peptide (ESAP) number


Legend: Cytotoxic evaulation of Ewing Sarcoma Antagonist Peptides. Ewing Tumor cell line TC32 and neuroblastoma cell line SKNAS were treated with 30 micromolar of Antennapedia fused ESAP peptides for 4 days. Black bar represents ESAP1, grey bars represent other peptides revelaed from phage display. M is media only control.

BRD9	NP_076413.3 ESAP1	161 EVVPVQVETAKKSKKPSREVISCMFEPEGNA 191 1 TMRGKKKRTRAN 12
TXNDC9	NP_005774 ESAP1	201 KFGTNFTKLEKKTIRGKKYDSDSDDD 226          112
MLL3	NP_733751.2 ESAP1	1281 GIGGFMVRQRSRTGQGKTKRSVIRK 1305 1TMRGKKKRTRAN- 12
MLL3	NP_733751.2 ESAP1	3591 QLYSDIIPEEKGKKKRTRKKKRDDDAESTK 3620  1TMRGKKKRTRAN 12
DDX27	NP_060365.7 ESAP1	1 MVLAQRRRGGCEKLRAGPQAVLASGSGFCD 30 1TMRGKKKRTRAN 12
DDX27	NP_060365.7 ESAP1	661 KEKIAKALQEFDLALRGKKKRKKFMKDAKK 690 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
DDX27	NP_060365.7 ESAP1	711 AERLAKRNRRAKRARAMPEEEPVRGPAKKQ 740  1


Legend: Blast results of ESAP1. Identity of amino acids was shown with vertical lines.




Legend: Coimmunoprecipitations with potential cognate protein and FLI1 antibodies




Legend: Binding of alanine substituted ESAP1 to EWS-FLI1





Legend: Caspase-3 activity assay. TC71 cells were treated with ESAP1 peptide for 24 hours. Caspase-3 activity was measured and normalized to non-treated TC71 caspase-3 basal activity.



Legend: Percent death caused by ESAP1 treatment. Death cell fractions were obtained from DNA histogram of either synchronozed or non synhronized cells that were treated with ESAP1. represent cells without any treatment. represent cells blocked with Nocadozole and released without any further treatment. ESAP1 treated cells without Nocodozle block. represent cells blocked with Nocadozole then treated with ESAP1.